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Abstract
Background: Current staging methods such as tumor thickness, ulceration and invasion of the sentinel node are known to
be prognostic parameters in patients with malignant melanoma (MM). However, predictive molecular marker profiles for
risk stratification and therapy optimization are not yet available for routine clinical assessment.
Methods and Findings: Using tissue microarrays, we retrospectively analyzed samples from 364 patients with primary MM.
We investigated a panel of 70 immunohistochemical (IHC) antibodies for cell cycle, apoptosis, DNA mismatch repair,
differentiation, proliferation, cell adhesion, signaling and metabolism. A marker selection procedure based on univariate Cox
regression and multiple testing correction was employed to correlate the IHC expression data with the clinical follow-up
(overall and recurrence-free survival). The model was thoroughly evaluated with two different cross validation experiments,
a permutation test and a multivariate Cox regression analysis. In addition, the predictive power of the identified marker
signature was validated on a second independent external test cohort (n = 225). A signature of seven biomarkers (Bax, Bcl-X,
PTEN, COX-2, loss of b-Catenin, loss of MTAP, and presence of CD20 positive B-lymphocytes) was found to be an
independent negative predictor for overall and recurrence-free survival in patients with MM. The seven-marker signature
could also predict a high risk of disease recurrence in patients with localized primary MM stage pT1-2 (tumor thickness
#2.00 mm). In particular, three of these markers (MTAP, COX-2, Bcl-X) were shown to offer direct therapeutic implications.
Conclusions: The seven-marker signature might serve as a prognostic tool enabling physicians to selectively triage, at the
time of diagnosis, the subset of high recurrence risk stage I–II patients for adjuvant therapy. Selective treatment of those
patients that are more likely to develop distant metastatic disease could potentially lower the burden of untreatable
metastatic melanoma and revolutionize the therapeutic management of MM.
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Introduction
Cutaneous malignant melanoma (MM), represents the most
common cause of death from skin cancer, and, apart from female
lung cancer, it is the tumor entity with the highest increase in
incidence worldwide [1]. MM is characterized by a multi-factorial
etiology. Sun exposure and genetic susceptibility have been
proposed as major etiological and predisposing factors and may
explain the reported increase of incidence to some degree [2].
De facto, the prognosis of patients with MM may only be
conditionally derived from clinical and histological parameters.
According to the AJCC 2009 classification [3], the findings of
vertical tumor thickness [4], tumor ulceration [5], and sentinel
node biopsy [6] represent the most dominant prognostic factors. In
stage pT1 melanomas (#1.00 thickness), the mitotic rate
(histologically defined as mitoses/mm2) has to be considered as
additional prognostic parameter [3].
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In MM, multiple cellular factors are known to be deregulated in
the initiation and progression phase of the tumor; among these are
protein regulators of the cell cycle, apoptosis, signal transduction,
cell adhesion and matrix digestion. A plethora of single biomarkers
have been evaluated for outcome prediction in melanoma patients;
e.g. Weinlich and coworkers identified metallothionein expression
as an independent negative marker of melanoma progression in
thin primary tumours [7]. Despite the fact that hundreds of such
studies sought to assess the potential prognostic value of molecular
markers in predicting the course of cutaneous MM, there are only
two prognostic models with potential for translation into the clinic.
Gould-Rothberg et al. [8] published a genetic-algorithm based
five-marker solution, and Kashani-Sabet et al. [9] reported a
three-marker model. However, no predictive molecular profiles for
therapy optimization applicable for routine clinical assessment of
MM are available, according to the latest review meta-analyses
[10,11].
To this end, we examined the immunohistochemical (IHC)
expression of 70 candidate biomarkers of MM including regulating
proteins of the cell cycle and apoptosis control, factors of signal-
transduction, cell adhesion, transcription-factors, differentiation,
and melanoma-specific antigens using tissue microarrays (TMAs).
The study was based on extensive follow-up investigation of a total
of 589 patients with primary MM from two independent cohorts,
and was initiated to identify a clear set of reliable IHC markers for
routine clinical assessment of patients with primary MM. Accord-
ingly, this biomarker study aimed at identifying an independent
prediction model for clinical outcome in patients with MM.
Materials and Methods
Ethics Statement
The study for both cohorts was approved by the local scientific
ethics committees (approval no.: 07/093 for Regensburg and MC-
028/08 for Hamburg).
Tissue Microarrays (TMAs)
TMAs were constructed as described previously [12] and based
on primary melanoma material, collected between 1994 and 2006.
TMA 1, the primary cohort, contained single tissue punch samples
from 364 consecutive (non-selected), formalin-fixed, paraffin-
embedded MMs of 364 different patients and were from the
Department of Dermatology, University Hospital of Regensburg,
Germany. TMA 2, the secondary cohort (independent external
validation cohort), consisted of consecutive (non-selected) MM
samples from 235 patients of the Department of Dermatology,
University Hospital Hamburg-Eppendorf, Germany. TMA 2
contained two tissue cores per melanoma specimen. For patients
with multiple subsequent neoplasms, only initial and single
primary MMs were included. H&E-stained slides of all MMs
were evaluated by two histopathologists (TV, PJW). The
clinicopathological characteristics of the two independent cohorts
of melanoma patients are given in Table S1. Clinical follow-up
data, provided by the local tumor registries, were available for all
patients of the primary cohort (n = 364) and 231 patients of the
secondary cohort. Patients were censored at 120 months, if their
follow-up exceeded the 10-year scope of the study. The
retrospective study implemented the REMARK guidelines [13].
Selection of Candidate Biomarkers
The primary antibodies used in this study were selected for
reporting on key aspects of apoptosis, cell cycle, signal transduc-
tion, cell adhesion, differentiation and proliferation, and tumor
metabolism (Table S2). The candidate markers were chosen
because of their described role in MM in the literature [10,11,14]
or on the basis of previous studies by our group [12,15].
Immunohistochemical Analysis
Paraffin-embedded preparations of melanoma tissues were
screened for protein expression according to standardized IHC
protocols as described previously [12,15]. Immunohistochemical
stainings were performed for 70 different primary antibodies
(source and concentrations are listed in Table S2). Negative
controls were obtained by omitting the primary antibody.
Specificity of commercial antibodies of the seven-marker signature
has been thoroughly tested by immunoblotting (Figures S1),
immunohistochemical analysis of melanocytes and melanoma cell
lines using a cell pellet microarray (Figure S2), and immunostain-
ing of whole melanoma sections (Figures S3A–D). Nocito et al.
[16] have already shown that intra-tumour heterogeneity does not
significantly affect the ability to detect clinico-pathological
correlations on tissue microarrays (TMAs), probably because of
the large number of tumors that can be included in TMA studies.
Figures S3A–D show whole tissue sections of primary malignant
melanomas stained for our seven-marker signature. Only Bax and
MTAP immunoreactivity was patchy in some cases (Figure S3A)
but homogeneous in most of the remaining ones (S3B–D).
Two dermatohistopathologists (SM, ML) performed a blinded
evaluation of the stained slides. In case of discordant scoring results
a consensus score was assigned. Cytoplasmic and nuclear
immunoreactivity were evaluated using a stepwise scoring system
(0 to 4+): 0 (negative): no cytoplasmic staining or 0% of cell nuclei
stained; 1+: weak cytoplasmic staining or less than 20% of cell
nuclei stained; 2+: moderate cytoplasmic staining or 21 to 50% of
cell nuclei stained; 3+: strong cytoplasmic staining or 51 to 90% of
cell nuclei stained; 4+: very strong cytoplasmic staining or nuclear
staining greater than 90%. This semiquantitative scoring system
was consistently used for all 70 markers analyzed. TMA spots with
a lack of tumor tissue or presence of necrosis or crush artifact were
excluded from the analysis. For the validation cohort (TMA 2), a
single score was assigned, taking the strongest immunoreactivity of
the two spots into account.
Statistical Analysis
P-values lower than 0.05 were considered to indicate statistical
significance. Statistical analyses were conducted using R version
2.11. A biomarker signature for prognosis of patients with
melanoma was developed and validated in three major steps:
A) Model Discovery. First, the prognostic value for each of
the of the 70 markers that met all quality-control steps was assayed
by univariate Cox proportional hazards regarding overall survival,
and those markers reaching significance at p= 0.05 with a false-
discovery rate of 0.15 were included in subsequent model
building. A risk score was calculated for each patient by a linear
combination of the univariate Cox regression coefficients and the
corresponding IHC measurements x~ x1,x2, . . . ,xD,f g, where D
is the number of markers in the signature. Single can be not
available due to missing TMA spots. Finally, the score is
normalized by the number of markers measured:
score xð Þ~
XD
i~1
bixið Þai
 !, XD
i~1
ai
 !
,
ai~
1, ifxiexists
0, ifxiismissing
(
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Table 1. Univariate Cox proportional hazard regeression models.
No. Variable Coefficients Std. Error P-Value Hazard ratio 95% CI
1 AKT3 0.188 0.164 0.252 1.206 0.875 1.663
2 BAX 0.441 0.091 ,0.001 1.554 1.301 1.857
3 BCL2 20.098 0.087 0.260 0.907 0.765 1.075
4 BCL2L1 0.092 0.086 0.285 1.096 0.926 1.298
5 Bcl-X 0.391 0.138 0.005 1.479 1.128 1.940
6 BMI1 20.043 0.104 0.677 0.958 0.781 1.174
7 B-Raf 0.123 0.081 0.130 1.130 0.965 1.325
8 Caveolin 20.028 0.114 0.806 0.972 0.777 1.217
9 CD166 0.089 0.173 0.606 1.094 0.778 1.536
10 CD20 0.547 0.188 0.004 1.728 1.195 2.498
11 CD44 20.154 0.107 0.150 0.857 0.695 1.057
12 CDK2 0.146 0.077 0.057 1.158 0.996 1.345
13 c-Kit 20.119 0.068 0.082 0.888 0.776 1.015
14 c-Myc 0.044 0.075 0.558 1.045 0.903 1.209
15 COX-2 0.297 0.123 0.016 1.345 1.058 1.710
16 CTNNB1 20.340 0.108 0.002 0.712 0.577 0.879
17 CXCR4 20.025 0.084 0.763 0.975 0.827 1.150
18 CyclinA 0.261 0.350 0.456 1.298 0.654 2.575
19 Cyclin-D1 0.174 0.091 0.057 1.190 0.995 1.424
20 E-Cadherin 20.118 0.068 0.081 0.889 0.778 1.015
21 ephB2 0.054 0.119 0.648 1.056 0.836 1.333
22 ephrinB2 0.005 0.120 0.968 1.005 0.794 1.272
23 Ezrin 20.074 0.080 0.357 0.929 0.795 1.086
24 FAS 0.103 0.126 0.410 1.109 0.867 1.418
25 FZD7 0.232 0.108 0.032 1.262 1.020 1.560
26 Glut-1 0.042 0.088 0.636 1.043 0.877 1.240
27 HIF1A 0.117 0.112 0.297 1.124 0.902 1.400
28 HMB 45 0.038 0.081 0.638 1.039 0.886 1.218
29 IGF2 20.168 0.100 0.093 0.845 0.695 1.029
30 iNOS 0.149 0.081 0.067 1.160 0.990 1.360
31 ITGA4 (CD49d) 0.407 0.096 ,0.001 1.502 1.245 1.812
32 Ki-67 0.046 0.137 0.735 1.047 0.801 1.370
33 L1CAM 20.005 0.104 0.961 0.995 0.811 1.220
34 Melan A 0.082 0.087 0.344 1.085 0.916 1.286
35 Melanin 0.112 0.080 0.160 1.119 0.957 1.308
36 MHCI 20.080 0.108 0.461 0.923 0.747 1.142
37 MITF 20.127 0.083 0.124 0.881 0.749 1.036
38 MLH1 0.254 0.088 0.004 1.290 1.086 1.531
39 MSH2 0.055 0.102 0.588 1.057 0.865 1.291
40 MTAP 20.621 0.231 0.007 0.537 0.342 0.845
41 MTSS1 20.016 0.148 0.913 0.984 0.736 1.316
42 MUM1p 0.053 0.090 0.559 1.054 0.884 1.257
43 NFKB 20.083 0.085 0.329 0.920 0.779 1.087
44 NRAS 0.206 0.143 0.151 1.228 0.928 1.626
45 p14 0.039 0.115 0.730 1.040 0.831 1.302
46 p15 20.187 0.111 0.092 0.829 0.667 1.031
47 p16 20.051 0.083 0.540 0.950 0.808 1.118
48 p21 0.134 0.084 0.110 1.143 0.970 1.347
49 p27 20.091 0.097 0.347 0.913 0.756 1.104
50 p53 0.141 0.073 0.054 1.152 0.998 1.330
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Based on this risk score, patients were assigned to a high risk
group and a low risk group, split at the 50th percentile (median) of
all scores. Thus, the final model consists of the coefficient vector b
and the median threshold h. Nonparametric Kaplan-Meier
estimators [17] were used to analyze overall survival and
recurrence-free survival. Differences between survival estimates
were assessed with the log-rank test (LRT) [18]. Finally, a
multivariable Cox regression model was adjusted, testing the
independent prognostic relevance of our risk score. Besides the
proposed biomarker signature, age, gender, tumor thickness, Clark
level, and nodal status were included in the Cox model as
covariates.
B) Internal Model Validation. The validity of the learning
procedure and hence the accuracy of the signature was assessed in
three different validation experiments. The cross validation
experiments were conducted as follows:
1. Divide the patients into K cross-validation folds (groups) at
random.
2. For each fold k = 1, 2, …, K.
a) Find a subset of univariate statistical significant (LRT
p,0.05) predictors for the overall survival, using all
of the patients except those in fold k.
b) Filter the selected predictors based on a false
discovery rate (FDR) of 0.15.
c) Using just this subset of predictors, build a multivar-
iate linear model, using all of the patients except
those in fold k.
d) Use the model to predict the scores for the patients in
fold k.
3. Aggregate the out-of-bag predictions of all patients and split
them in two groups based on the median predicted score.
4. Calculate the Kaplan-Meier estimator for each group and
report the LRT p-value of their difference in survival
expectation.
First, leave-one-out cross validation was employed by excluding
one patient at a time from the training set and subsequently scoring
the left out patient with the signature learned from the rest of the
patients. Repeating this procedure 364 times yields a leave-one-out
score estimate for each patient in the study. Second, 10-fold cross
validation was conducted by partitioning the dataset into 10 parts of
equal size using 90% of the patients for learning and 10% for
validation.Theprocedurewasrepeated10timesresulting ina10-fold
cross validation score for each patient. The third validation
experimentwas conducted to assess, if the proposedmarker selection
procedure is prone to over fitting.To this end, the target variablewas
randomlypermuted and amodelwas learned to predict the risk score
based on this distorted data.
C) External Model Validation. Our marker signature was
validatedonanexternal testcohort fromHamburg,Germany.Again,
a risk scorewas calculated for each patient by a linear combination of
theunivariateCoxregressioncoefficientsb fromthe initial test cohort
and the IHCmeasurements of the external cohort. Based on this risk
score, patientswereassigned toahigh risk groupanda lowrisk group,
split at the 50th percentile (median) of all scores. Finally, a
multivariable Cox proportional hazards model was adjusted, testing
the independent prognostic relevance of our risk score. Besides the
Table 1. Cont.
No. Variable Coefficients Std. Error P-Value Hazard ratio 95% CI
51 p75 (NGFR) 0.100 0.116 0.386 1.105 0.881 1.386
52 P-Cadherin 20.104 0.096 0.279 0.902 0.747 1.088
53 PGF 0.031 0.066 0.646 1.031 0.905 1.175
54 Phospho-Akt (Thr308) 0.134 0.096 0.161 1.144 0.948 1.380
55 Phospho-CTNNB1 (Ser33/37/
Thr41)
0.016 0.081 0.842 1.016 0.867 1.191
56 Phospho-Rb (Ser807/811) 20.138 0.293 0.637 0.871 0.491 1.546
57 Phospho-Stat1 (Ser727) 0.107 0.098 0.275 1.113 0.918 1.348
58 PMP2 0.078 0.099 0.430 1.081 0.890 1.313
59 PPARA 20.147 0.098 0.135 0.863 0.712 1.047
60 PTEN 0.272 0.102 0.008 1.312 1.075 1.601
61 Rb 0.233 0.156 0.135 1.263 0.930 1.714
62 Ro52 20.187 0.234 0.425 0.830 0.525 1.312
63 S1P1 0.049 0.079 0.533 1.051 0.899 1.228
64 SKP2 0.047 0.085 0.580 1.048 0.887 1.238
65 Stat 1 0.010 0.114 0.928 1.010 0.808 1.263
66 Survivin 20.104 0.094 0.269 0.901 0.749 1.084
67 TGFB1 20.118 0.108 0.276 0.889 0.719 1.099
68 TOP2A 20.205 0.092 0.026 0.814 0.680 0.975
69 VEGFR2 20.048 0.097 0.619 0.953 0.788 1.153
70 XIAP 0.037 0.088 0.673 1.038 0.874 1.233
Bold face representing variables with p-values ,0.05.
CI, confidence interval.
doi:10.1371/journal.pone.0038222.t001
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proposed biomarker signature, age, gender, tumor thickness, Clark
level, and nodal status were included in the Coxmodel as covariates.
Results
Discovery of the Seven-Marker Signature
Prognostic power of the 70 markers was assessed by calculating
univariate proportional hazard models [19], yielding eleven
markers significantly associated with overall survival (Table 1).
To correct for multiple testing, the false discovery rate (FDR)
procedure [20] was applied with a FDR of 0.15 reducing the set of
significantly associated markers to nine (Figure 1) which were
correlated with death from any cause: MTAP and b-Catenin were
so called ‘‘protective markers’’, where loss of expression was
associated with worse outcome. The remaining other seven
markers were assigned ‘‘risk markers’’.
Finally, CD49d, an a4-integrin (ITGA4) participating in cell-
surface mediated signaling and adhesion, was dropped because the
antibody failed our validation processes due to generation of
multiple bands on western blot using a panel of melanoma cell
lines and melanocytes [21] (Figure S1). Exclusion of CD49d
resulted in a final seven biomarker signature. Besides CD49d, Bcl-
X, MTAP, and to a lesser extent CTNNB1 and Bax also displayed
multiple bands (Figure S1). However, all antibodies except CD49d
showed at least one main (strongest) western blot signal.
Among the 362 patients of the primary cohort, patients with a
high-risk seven-marker signature had a shorter median overall
survival than the patients with a low-risk seven-marker signature
(88 months versus not reached) and the difference between the two
patient groups was significant (p,0.00001) (Figure 2A). The high-
risk seven-marker signature was associated with a median
recurrence-free survival of 33 months, whereas the low-risk
seven-marker signature was associated with a median recur-
rence-free survival of 88 months (p,0.001) (Figure 2B). The
heatmap in Figure 2C shows the IHC expression profiles of these
362 tumor specimens from the primary cohort ordered by their
predicted risk score, indicating no high correlation between the
selected markers. Figure S4 depicts all correlations between the
markers of interest. Having the same sign, risk markers are
naturally slightly correlated, but the maximal correlation between
Bcl-X and COX-2 is only 0.36.
Comparing high-risk with low-risk patients (Table 2) based on
their seven-marker risk score showed a significant difference in
tumor thickness (p,0.001) and Clark level (p,0.001) and no
difference in nodal status (p = 0.08), sex (p = 1) and age (p = 0.26).
Risk scores significantly increased with increasing Clark levels
(Figures 3A and 3B). Patients with nodular malignant melanomas
(NM) showed the highest risk scores. Dot blots of risk scores for the
various histological subtypes of malignant melanoma as classified
by the ICD-10 are given in Figure 4.
According to multivariate Cox regression analysis, the seven-
marker risk score, age, Clark level, and sex, were significantly
associated with death from any cause among the 320 patients (113
events, 44 observations were deleted due to missing values).
Table 2 summarizes the characteristics of variables that were
included in the multivariate Cox model.
A subgroup analysis of 253 patients with a tumor depth of
#2 mm revealed that those 148 patients with a high-risk marker
Figure 1. Hazard Ratios of the Nine-Marker Signature learned by the FDR selection procedure. Markers with a hazard ratio smaller than
1.00 represent ‘‘protective markers’’ (MTAP, b-Catenin). Those with hazard ratios larger than 1.00 represent ‘‘risk markers’’ (Bax, Bcl-X, infiltration with
CD20 positive B-lymphocytes, CD49d, COX-2, MLH1 and PTEN).
doi:10.1371/journal.pone.0038222.g001
Seven-Marker Signature in Malignant Melanoma
PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e38222
signature had a significantly (p,0.01) shorter overall survival
(Figure 5A) and recurrence-free survival (p,0.01) than the 105
patients with a low-risk marker signature (Figure 5B).
Internal Statistical Validation of the Seven-Marker
Signature
The cross validation experiments showed comparable results
and demonstrated that learning a marker signature for overall and
recurrence-free survival was feasible and reproducible (Figures 5C–
F). For leave-one-out cross validation, patients with high risk scores
had a median survival of 94 months whereas median survival for
patients with low risk signature was not reached (Figure 5C). The
difference in survival expectance between patients with high-risk
score and low-risk score was highly significant (p,0.0001).
Although 10-fold cross validation has lower bias and higher
variance, the difference between the high risk and low risk group
(94 month versus not reached) was still significant (p,0.001,
Figure 5E). In contrast to the cross validation experiments it was
not possible to learn a signature to predict permuted labels
(p.0.5), which indicates that the proposed learning procedure is
not over fitting (Figure 5G). All coefficients and confidence
intervals of the seven-marker signature are reported in Figure 5H.
Figure 2. The Seven-Marker Signature and Survival of 362 Patients with Primary MM. Panels A and B show Kaplan-Meier estimates of
overall and recurrence-free survival for high risk patients (red) and low risk patients (green) from the primary cohort according to the final seven-
marker signature (Panels A, B). Equality in survival expectance of the subgroups is assessed by the log-rank test. The difference between high risk
patients and low risk patients is highly significant (p,0.001) for the seven-marker signature. Panel C shows the IHC expression profiles of 362 tumor
specimens from the primary cohort ordered by their predicted risk score. Each column represents an individual patient consisting of the expression
values of the seven-marker signature (5 risk markers and 2 protective markers). The magnitude of the corresponding risk score is plotted below for
181 low risk patients (green) and 181 high risk patients (red). IHC expression values were scaled between 0 (light blue) and 1 (dark blue) for plotting
only. White cells represent missing values (n.a.).
doi:10.1371/journal.pone.0038222.g002
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Model Validation of the Seven-Marker Signature on an
External Test Cohort
The clinical characteristics of the 225 patients in the external
test cohort are listed in Table S1. Patients with a high-risk marker
signature had a significantly (p,0.0001) shorter median overall
survival compared to patients with a low-risk signature (Figure 6A).
Table 2. Clinical characteristics of the primary cohort of patients with MM (TMA 1).
High risk (N=181) Low risk (N=181) p-Value: high vs. low risk Hazard ratio (95% CI) #3 p-Value #3
7-Marker risk score 0.26760.092 0.001760.12 ,,0.0001#1 5.1 (1.4–18.2) 0.012*
Age – yr 59.5615.0 57.7614.9 0.263#1 1.03 (1.02–1.05) 0.000011***
Tumor thickness – mm 2.5262.38 1.4062.21 0.00000646#1 1.05 (0.97–1.14) 0.24
Clark level 3.6660.739 2.9360.83 ,,0.0001*** 1.8 (1.4–2.5) 0.000098***
Sex – no. of patients (%)
Male 105 (58) 89 (49.2) 1#2 1.9 (1.3–2.8) 0.0019**
Female 76 (42) 92 (50.8)
Nodal status (%)
N0 158 (90.8) 159 (95.8) 0.084#2 1.6 (0.8–3.2) 0.15
N1-N3 16 (9.2) 7 (4.22)
#1Welch two sample t-test,
#2Fisher’s exact test,
#3Multivariate Cox regression,
***p-Value ,0.001.
Comparing high-risk patients (first column) with low-risk patients (second column) based on their seven-marker risk score showed a significant difference in tumor
thickness (p,0.001) and Clark levels (p,0.001), and no difference in nodal status (p = 0.084), sex (p = 1) and age (p = 0.263). Furthermore, hazard ratios and p-values
were reported for a multivariate Cox regression model comprising all listed variables. Regarding overall survival the seven-marker risk score was statistically significant
(p,0.05) independent of sex, age, nodal status, clark level and tumor thickness. Continuous variables are reported with mean and standard deviation and categorical
variables are listed with number of counts and percentages.
doi:10.1371/journal.pone.0038222.t002
Figure 3. Dot blots of risk scores for different Clark levels in the
training (Panel A) and testing (Panel B) cohort. Horizontal lines
represent median risk scores for each subgroup.
doi:10.1371/journal.pone.0038222.g003
Figure 4. Dot blot of risk scores for the various histological
subtypes of melanoma as classified by the ICD-10 (Interna-
tional Statistical Classification of Diseases and Related Health
Problems, 10th revision). SSM, superficial spreading melanoma;
LMM, lentigo maligna melanoma; NM, nodular melanoma; NOS, not
otherwise specificed; ALM, acral lentiginous melanoma. Horizontal lines
represent median risk scores for each subgroup.The aim of this study
was to provide a maximum of prognostic and therapeutically relevant
information by a minimum of markers combined in a clear signature.
For the sake of clinical feasibility and cost saving, an IHC marker set
suitable for routine clinical assessment should be based on a limited
number of antibodies. Accordingly, the nine-marker signature was
reduced by the risk marker with the lowest Cox regression coefficient b,
i.e. MLH1 (b= 0.254).
doi:10.1371/journal.pone.0038222.g004
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Comparing high-risk patients (Table 3) with low-risk patients
based on their seven-marker risk score showed a significant
difference in tumor thickness (p,0.001) and Clark levels
(p,0.001), but no difference in sex (p= 1), age (p= 0.27) and
nodal status (p = 0.34).
According to multivariate Cox regression including the seven-
marker risk score, sex, age, Clark level, nodal status, and tumor
thickness, the seven-marker signature was significantly associated
with overall survival (p,0.05, Table 3). Additionally, the
recurrence-free survival differed significantly between the two risk
groups (p,0.001; Figure 6B).
Discussion
In this retrospective study of 364 melanoma patients, we
identified an independent seven-marker signature of prognosis.
Notably, the predictive power of the signature was carefully
validated and confirmed on a secondary independent external test
cohort (n = 225). With a total of 27,055 specimens of primary
MMs analyzed by IHC, this TMA study is unmatched in the
literature. An individual patient’s risk score can easily be
calculated given the immunoreactivity scores for the seven markers
and the estimated coefficients (Figure 5H). Figure 7 shows stained
TMA specimens illustrating the Seven-Marker Signature for a
patient with a high-risk and another patient with a low-risk
melanoma.
One of the main statistical problems in large scale IHC studies
are missing values in the design matrix due to missing or corrupt
spots on the TMA. The more markers are investigated the higher
the chance that at least one value is missing per patient. Frequently
this problem is tackled by either sacrificing a larger number of
patient records or by employing volatile multiple imputation
techniques. In this study 9.3% of values were missing, reducing the
set of patients with all IHC measurements from 364 to 170.
Algorithms like random survival forests [22] and ensemble
learning with gradient boosting [23] are capable of dealing with
missing values, but lead to models that are not intuitively
interpretable and difficult to implement in clinical practice. To
overcome these problems we employed a learning procedure
which is invariant to missing values and results in an easily
interpretable and practically applicable linear model.
In early disease stages, application of an IHC based test to
examine a MM patient’s tumor tissue at a molecular level suggests
itself. Even though melanoma was among the first cancers
recognized as a target for practical application of microarray
analysis starting in 1996 [24], the transition of gene expression
results to diagnostic applications with clinical impact has not been
shown yet in MM. Microarray studies produced a plethora of data
and have provided useful insights into the molecular biology of
melanoma (reviewed in [25]). However, analysis of different
histological subtypes of melanoma, expression analysis of mainly
melanoma metastases, and lack of homogeneity of patient cohorts
hampered the interpretation of these data [25]. Furthermore,
routine supply of fresh frozen MM tissue for microarray based
assays seems virtually impossible. Also, use of RT-PCR based tests
are complicated by the need for pure populations of neoplastic
melanoma cells, and has not yet resulted in a breakthrough in
melanoma diagnosis or management of melanoma patients. Our
Figure 5. Statistical Analyses. Panel A, B. The Seven-Marker Signature and Survival of Patients with a Tumor Thickness #2.0 mm
(TMA 1). Kaplan-Meier estimates show a significantly lower overall (p,0.01, Panel A) and recurrence-free survival (p,0.01, Panel B) for patients with
a comparatively low tumor thickness #2.0 mm but high-risk score. Panel C, D. Leave-One-Out Cross Validation. To investigate the
generalization error of the models produced by the FDR signature learning procedure a leave-one-out cross validation experiment was conducted on
the primary cohort of 362 MM patients. The resulting risk score could significantly (p,0.001) differentiate between patients with higher or lower
overall survival expectance. The two patient groups also significantly (p,0.01) differ in recurrence-free survival. Panel E, F. 10-Fold Cross
Validation. In addition, the FDR marker selection procedure was tested by a 10-fold cross validation experiment on the 362 patients of the primary
cohort (TMA 1) resulting in still significant estimates for overall survival (p,0.001; Panel E) and recurrence-free survival (p,0.05; Panel F). Panel G.
Permutation Test. In addition to the cross validation experiments a permutation test was conducted to assess if the signature learning procedure is
over fitting the data set. The resulting signature, which was learned on permuted overall survival data, was not able (p = 1) to discriminate between
patients with differing survival expectance. This result indicates that the proposed learning procedure does not over fit the data. Panel H.
Coefficients and Confidence Intervals of the Seven-Marker Signature. The coefficients from the univariate Cox proportional hazard models
are used in a weighted linear combination to predict the risk score for each patient. Markers with negative coefficients represent protective markers
(MTAP, b-Catenin); those with positive coefficients risk markers (Bax, Bcl-X, PTEN, COX-2, and presence of CD20 positive lymphocytes,).
doi:10.1371/journal.pone.0038222.g005
Figure 6. Validation of the Seven-Marker Signature and the FDR Marker Selection Procedure. Kaplan-Meier estimates of overall (Panel A)
and recurrence-free survival (Panel B) for the independent external test cohort of 225 patients (TMA 2) confirm the predictive prognostic power of
the signature (p,0.001).
doi:10.1371/journal.pone.0038222.g006
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defined seven-marker signature was of independent prognostic
relevance in two independent patient cohorts. For the practitioner,
the assessment of this set of seven IHC markers promises to be a
helpful tool to answer the crucial question ‘‘whom to treat, and
how to treat’’, especially in the adjuvant setting after surgical
excision of early-stage and localized primary MM (Stage I to IIa).
With MTAP, COX-2 and Bcl-X, three markers of the seven-
marker signature offer direct therapeutic implications, since the
corresponding drugs have already been approved by the FDA.
Currently, in the adjuvant treatment of MM, interferon alpha is
the only clinically accepted therapeutic agent providing a
significant (recurrence-free) survival benefit for a small but distinct
percentage of patients [26]. On account of the serious side effects
and the high costs of the therapy, only those patients with a
realistic chance to benefit from interferon should receive this
treatment. We have recently shown that there is a clear association
between MTAP expression in the primary melanoma and
melanoma progression and, even more importantly, response to
interferon treatment [12,27]. This gives rise to the hypothesis that
interferon response may be correlated with the expression of
interferon response genes such as MTAP.
Cyclooxygenase 2 (COX-2) may represent another promising
therapeutic target. Cyclooxygenases catalyze the first rate-limiting
step in the conversion of arachidonic acid to prostaglandins.
COX-2 is expressed in various tumor types and levels of COX-2
expression have been shown to correlate with invasiveness and
prognosis in some tumor entities, including epithelial and
melanocytic skin cancer [15,28]. So far the benefit of COX-2-
inhibitors has not been studied in the adjuvant treatment of early-
stage melanomas to prevent metastasis. In the second-line
treatment of advanced metastatic melanoma disease, however, a
survival benefit was shown for targeted combined therapy using
COX-2 inhibitors and PPARG-agonists for anti-inflammatory
treatment together with low-dose metronomic chemotherapy [29].
Considering this observation and the fact that melanoma patients
with COX-2-positive primary tumors bear a significantly higher
risk of tumor recurrence [15], introduction of COX-2 inhibitors
for primary adjuvant treatment of these patients seems obvious.
One additional marker, Bcl-X, has been targeted in preclinical
tests and several targeting agents are in the clinical testing phase by
now [30]: Bcl-X is related to the anti-apoptotic Bcl-2 protein
family. Overexpression of these anti-apoptotic proteins protects
cancer cells against death signals of apoptosis. Interestingly,
tumors expressing high levels of Bcl-2 or Bcl-X are often found
to be resistant to chemotherapeutic agents or radiation therapy
[31]. In recent years, non-peptidic cell permeable ‘‘small molecule
inhibitors’’ (SMIs) against antiapoptotic proteins like Bcl-2 or Bcl-
X have been identified. SMIs inhibit distinct protein-protein
interactions by blocking specific binding sites of the target
molecule, thus supporting the apoptotic machinery [30]. Inhibi-
tion of Bcl-X may exert a synergistic effect with conventional
treatments like chemo- or radiation therapy. Regarding MM
therapy, this effect would be a decisive therapeutic success.
Presence of CD20-positive B-lymphocytes within or adjacent to
MM tissue (Figures 8A–D ) was among the top seven biomarkers.
However, the role of B-lymphocyte infiltration in MM is unknown
and needs further investigation. The CD20-antigen is known to be
an effective therapeutic target in the treatment of patients with
CD20-positive B-Cell-Non-Hodgkin-Lymphomas. The monoclo-
nal chimeric antibody Rituximab is indicated for alternative
immunotherapy [32]. In MM, several subpopulations - some with
stem cell-like characteristics - have been described including one
with expression of CD20 (reviewed in [33]). In our study, only very
few cases showed infiltrating CD20 positive B-lymphocytes
(Figure 2E), comprising a very narrow dynamic range of this
marker. However, even a six-marker signature without CD20 was
significantly associated with overall and recurrence-free survival
(Figures 9A and 9B).
The tumor-suppressor gene phosphatase and tensin homolog
(PTEN) is one of the most commonly inactivated genes in human
cancer and has been identified as lost or mutated in melanoma
[34]. An established consequence of PTEN inactivation is the
Table 3. Clinical characteristics of the external test cohort of patients with MM (TMA 2).
High risk (N=150) Low risk (N=75)
p-Value: high vs. low
risk Hazard ratio (95% CI)#3 p-Value#3
7-Marker risk score 0.27060.098 0.0460.071 ,,0.0001#1 14.45 (1.68–124.49) 0.015*
Age – yr 55.2616 52.666.6 0.267#1 1.02 (1.00–1.04) 0.11
Tumor thickness – mm 2.5562.67 1.0861.17 0.0000000512#1 1.19 (1.07–1.32) 0.0017**
Clark level 3.5860.814 2.9760.87 0.0000016#1 1.81 (1.06–3.09) 0.030*
Sex – no. of patients (%)
Male 81 (55.1) 41 (54.7) 1#2 1.55 (0.84–2.85) 0.16
Female 66 (44.9) 34 (45.3)
Nodal status (%)
N0 131 (93.6) 73 (97.3) 0.34#2 3.18 (1.27–7.94) 0.013*
N1–N3 9 (6.43) 2 (2.67)
#1Welch two sample t-test,
#2Fisher’s exact test,
#3Multivariate Cox regression,
*p-Value ,0.05,
***p-Value ,0.001.
Comparing high-risk patients (first column) with low-risk patients (second column) based on their seven-marker risk score showed a significant difference in tumor
thickness (p,0.001) and Clark levels (p,0.001), and no difference in sex (p = 1), age (p = 0.267) and nodal status (p = 0.34). Furthermore, hazard ratios and p-values were
reported for a multivariate Cox regression model comprising all listed variables. Regarding overall survival the seven-marker risk score was statistically significant
(p,0.05) independent of sex, age, nodal status, clark score and tumor thickness. Continuous variables are reported with mean and standard deviation and categorical
variables are listed with number of counts and percentages.
doi:10.1371/journal.pone.0038222.t003
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constitutive aberrant activation of the phosphatidylinositol-3-
kinase (PI3K)-signaling pathway that drives uncontrolled cell
growth, proliferation, and survival [35]. In general, prediction of
PI3K-signaling pathway activation based on PTEN IHC expres-
sion status is unfeasible since inactivation of PTEN is achieved by
either gene mutation or deletion [34]. Figure S5 shows that some
melanoma cell lines show PTEN expression and concomitant
activation of the PI3K/AKT cascade. Alterations of the tumor
suppressor PTEN have already been linked with disease outcome
in patients with MM: Mikhail et al. have shown that loss of nuclear
PTEN expression was associated with aggressive tumor behavior
[36]. In contrast, we could show that strong cytoplasmic PTEN
expression was found only in high risk patients.
Most oncological findings regarding the Wnt/b-Catenin signal-
ing are derived from the analysis of colon, breast and kidney
carcinoma [37,38] where activation of the pathway has been
directly implicated in disease pathogenesis. The majority of
colorectal carcinomas carry inactivating mutations in the Adeno-
matous polyposis coli (APC) tumor suppressor which lead to
stabilization of b-Catenin, mimicking Wnt stimulation. Addition-
ally, mutations in the b-Catenin gene CTNNB1 were found in
colon cancer leading to the constitutive activation of b-Catenin/
LEF/TCF-dependent canonical signaling [39]. However, such
mutations are rarely found during melanoma development. In
contrast to findings in colon carcinoma and in line with a study by
Kuphal et al. [40], we show that b-Catenin protein was basically
cytoplasmic in melanomas in vivo. Regarding our risk score, loss of
cytoplamic b-Catenin expression was associated with worse
outcome of melanoma patients. Kuphal and co-workers also
demonstrated that the transcriptional activity of b-Catenin
regulating expression of b-Catenin target genes was not observed
in several melanoma cell lines, suggesting a cell type specific
regulation of b-Catenin function [40].
According to the data presented here, the seven-marker
signature might serve as a prognostic tool enabling physicians to
selectively triage, at the time of diagnosis and initial surgery, the
subset of high recurrence risk stage I–II patients for adjuvant
therapy. Selective treatment of those patients that are more likely
to develop distant metastatic disease could potentially lower the
burden of untreatable metastatic melanoma and revolutionize the
therapeutic management of MM. Prospective clinical trials are
necessary to validate the prognostic and therapeutic value of this
seven-marker signature and its benefit for routine clinical
assessment of MM. The utility of the algorithm in a practice
setting, where full heterogeneous tissue sections are used, is
currently being analyzed in a prospective clinical trial at the
Department of Dermatology, University of Regensburg, Ger-
many.
Figure 7. Immunohistochemically stained TMA specimens illustrating the Seven-Marker Signature for a patient with a high-risk and
another patient with a low-risk melanoma. The low-risk melanoma (Column C) showed a strong cytoplasmic staining for b-Catenin and MTAP,
respectively. Immunoreactivity of these two protective markers was not found in the high-risk melanoma (Column D). In contrast, the high-risk
melanoma demonstrated a moderate to strong cytoplasmic staining for Bax, Bcl-X, PTEN, COX-2, and infiltration with CD20 positive B-lymphocytes.
doi:10.1371/journal.pone.0038222.g007
Figure 8. High resolution images of case no. 137 on the tissue microarray. Serial sections of the tissue microarray (TMA 1) was
immunohistochemically stained with CD20 (Panel A, B) and HMB45 (Panel C, D) to show CD20 positive B-lymphocytes within and adjacent to
melanoma cells (case no. 137).
doi:10.1371/journal.pone.0038222.g008
Seven-Marker Signature in Malignant Melanoma
PLoS ONE | www.plosone.org 12 June 2012 | Volume 7 | Issue 6 | e38222
Supporting Information
Figure S1 Western blot analysis of the nine-marker
signature candidates in lysates of melanocytes and
human melanoma cell lines. Cultured cells were lysed in
4uC cold radioimmunoprecipitation assay buffer (RIPA Buffer Set,
Boehringer, Mannheim, Germany: 50 mM Tris-HCl, pH 7.5,
150 mM NaCl, 1% NonidetH P40, 0.5% sodium deoxycholate,
0.1% SDS, 1 CompleteTM Protease Inhibitor Cocktail Tablet).
Protein extracts (40 mg) were run on 8–15% polyacrylamide gels,
transferred to polyvinylidene fluoride (PVDF) membranes (Milli-
pore, Bedford, USA) and visualised by immunoblotting. Human
melanoma cell lines*, melanocytes and keratinocytes were
provided by Anja K. Bosserhoff, Institute of Pathology, University
of Regensburg, Germany. Whole cell lysates for positive controls
were provided by Abcam plc, 330 Science Park, Cambridge, CB4
0FL, UK. Whole cell lysates of human HaCaT keratinocytes were
provided by the DKFZ, Heidelberg, Germany.
(PDF)
Figure S2 Immunohistochemical analysis of the seven-
marker signature candidates using a microarray with
cell pellets of melanocytes and human melanoma cell
lines. In order to characterise the seven-marker signature
candidates, melanocytes and melanoma cell lines were trypsinized
and embedded in paraffin as a cell pellet. Sections of these cell
blocks were stained with antibodies against the seven-marker
signature. All immunohistochemical investigations were based on
an avidin-biotin peroxidase method with a 3-amino-9-ethylcarba-
zole (AEC) chromatogen. After antigen retrieval (steam boiler with
citrate-buffer, pH 6.0 or with Tris-EDTA-buffer, pH 9.0 for
20 min) immunohistochemistry was carried out applying the
ZytoChemPlus HRP Broad Spectrum Kit (Zytomed Systems,
Berlin, Germany) according to the manufacturer’s instructions.
Cytoplasmic and nuclear markers were visualized with AEC
solution (AEC+ High Sensitivity Substrate Chromogen, ready-to-
use, DAKO, Glostrup, Denmark). The red color of the AEC
substrate chromogen (3-amino-9-ethylcarbazole) is very beneficial
to rule out the possibility of a role of endogenous melanin in the
observed reactivity. All sections were counterstained with
hematoxylin (DAKO). Weblink to slides: http://histodb2.usz.ch/
dss/searchURL.
php?outputFormat = viewer&category = conference&confHash= -
275761229
(PDF)
Figure S3 Immunohistochemical analysis of the marker
heterogeneity of the seven-marker signature candidates,
staining a selection of whole slides for each marker.
Besides infiltrating CD20 positive B-Lymphocytes, the staining
distribution of the remaining six markers was rather homogenous.
(PDF)
Figure S4 Bar chart depicting Pearson correlation
coefficents between the markers of the signature.
(PDF)
Figures S5 Immunohistochemical characterization of
two melanoma cell lines regarding the phosphatidylino-
sitol-3-kinase (PI3)/AKT/mTOR cascade. In order to
characterise the melanoma cell lines that were used for our
western blot experiments, cells were trypsinized and embedded in
paraffin as a cell pellet. Sections of these cell blocks were stained
with antibodies against PTEN (Dako, clone 6H2.1, M3627,
dilution 1:200), P-Akt (Ser473) (Abcam, ab8932, dilution 1:150),
and P-S6 ribosomal protein (Ser235/236, Cell Signaling Tech-
nology, #2215, dilution 1:50). PTEN status of prostate cancer cell
lines is well known. PC3 cells typically have sustained a
homozygous deletion of PTEN and are therefore PTEN negative
(Panel A). In contrast LNCaP cells have a deletion of one allele
and a mutation of the other PTEN allele (McMenamin ME, et al.
(1999) Cancer Res 59:4291–4296) with consecutive PTEN
overexpression (Panel B). Both cell lines typically show activation
of the phosphatidylinositol-3-kinase (PI3)/AKT cascade, resulting
in expression of P-Akt and P-S6 ribosomal protein. The two
melanoma cell lines tested (HTZ 19d and IGR-1), both showed
expression of PTEN and activation of the phosphatidylinositol-3-
kinase (PI3)/AKT cascade (Panel C&D).
(PDF)
Table S1 Characterization and comparison of the
primary cohort (TMA 1) and the external test cohort
(TMA 2). Reported are the number of counts and the associated
percentages for all specimens on the tissue microarrays. CD49d
and MLH1 are not contained in the final seven-marker signature
and therefore were not analyzed on the external test TMA 2.
Missing values are listed as ‘‘unknown’’.
(XLS)
Table S2 Properties of the 70 biomarker candidates for
malignant melanoma immunohistochemically analyzed
in this study. All antibodies investigated are listed indicating
source, dilution, pattern of reactivity and positive control. The
Figure 9. The Six-Marker Signature (without CD20) and Survival of Patients with Malignant Melanoma. Kaplan-Meier estimates show a
significantly lower overall (p,0.00001, Panel A) and recurrence-free survival (p,0.01, Panel B) for melanoma patients with high-risk score.
doi:10.1371/journal.pone.0038222.g009
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described signature was statistically learned by the FDR selection
procedure from this pool of 70 biomarkers.
(DOCX)
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